Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 6/20 | 0.53 |
| ▸ | BTK | Q06187 | 12/20 | 0.46 |
| ▸ | MYLK | Q15746 | 1/20 | 0.44 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.42 |
| ▸ | BRAF | P15056 | 1/20 | 0.42 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2021714 | 0.92 | BTK (0.48) | EGFRBTK | |
| SCHEMBL2018649 | 0.90 | BTK (0.54) | BTKERBB2BRAFTNNI3K | |
| SCHEMBL2022836 | 0.89 | BTK (0.49) | EGFRBTK | |
| SCHEMBL2023481 | 0.89 | BTK (0.46) | EGFRBTKERBB2BRAFTNNI3K | |
| SCHEMBL2020248 | 0.87 | BTK (0.49) | BTKERBB2BRAFTNNI3K | |
| SCHEMBL2023711 | 0.87 | L3MBTL1 (0.52) | EGFRBTKERBB2BRAFTNNI3K | |
| SCHEMBL2021361 | 0.86 | BTK (0.46) | BTKERBB2BRAFTNNI3K | |
| SCHEMBL2021334 | 0.85 | MEN1 (0.50) | EGFRBTK | |
| SCHEMBL2022638 | 0.85 | EGFR (0.53) | EGFRBTK | |
| SCHEMBL2019802 | 0.84 | ABCG2 (0.54) | EGFRBTKBRAFTNNI3K |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580803-B2 | Substituted pyrrolo-aminopyrimidine compounds | ARQULE, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580803-B2 | Substituted pyrrolo-aminopyrimidine compounds | ARQULE, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580803-B2 | Substituted pyrrolo-aminopyrimidine compounds | ARQULE, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| WO-2011082273-A2 | SUBSTITUTED PYRROLO-AMINOPYRIMIDINE COMPOUNDS | ARQULE, INC. (US) | 2011-07-07 | — | — | WO | disclosed |
| US-20110160203-A1 | Substituted Pyrrolo-Aminopyrimidine Compounds | ARQULE, INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-20110160203-A1 | Substituted Pyrrolo-Aminopyrimidine Compounds | ARQULE, INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-20110160203-A1 | Substituted Pyrrolo-Aminopyrimidine Compounds | ARQULE, INC. (US) | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160203-A1 | Substituted Pyrrolo-Aminopyrimidine Compounds | DPYD, TYMP, DHFR | EGFR 1215/4885BTK 1600/4885MYLK 3144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.